ArticleIndian journal of ophthalmology2026
Atropine reinstates inflammation-induced dysregulation of dopamine and its receptors in human scleral cells: Implications for myopia therapy.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMyopia is a complex refractive disorder and a leading cause of visual impairment worldwide. Inflammation plays a crucial role in the onset and progression of myopia. This study aimed to investigate the role of atropine in modulating inflammation-induced alterations in dopamine and its receptors in primary human scleral cells under in vitro experimental conditions.
methodsHuman primary scleral cells were exposed to long-term inflammatory conditions in the presence or absence of atropine or dopamine hydrochloride. Following treatment, gene and protein expressions were analyzed for inflammatory markers, dopamine receptors, and extracellular matrix (ECM) using quantitative polymerase chain reaction, immunoblotting, and immunofluorescence. Secretory cytokines and dopamine levels were measured using an automated enzyme-linked immunosorbent assay system.
resultsIn primary human scleral cells, atropine treatment increases the dopamine receptor expression. Prolonged inflammatory stimulation led to a marked reduction in dopamine and its receptor (D1-D2) expression, which was effectively restored following atropine treatment in scleral cells. Under inflammatory conditions, atropine significantly suppressed pro-inflammatory cytokines expression at both the transcript and protein levels and mitigated the inflammation-induced dysregulation of ECM genes.
conclusionOur findings demonstrate atropine restores inflammation-induced dopaminergic and extracellular matrix dysregulation in human scleral cells, highlighting its dual anti-inflammatory and neuro-modulatory roles. The restoration of dopamine signaling and ECM balance underscores atropine's potential as a therapeutic agent for myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.